Merck Hep C Drug Zepatier OK'd
This article was originally published in Scrip
Merck & Co. gained the FDA's go-ahead on Jan. 28 to market Zepatier (elbasvir and grazoprevir) as a treatment for adults with chronic hepatitis C virus (HCV) genotypes (GTs) 1 or 4 infection, with or without ribavirin (RBV).
You may also be interested in...
With few remaining unmet needs in hepatitis C, Gilead, Merck and AbbVie are focusing on tough-to-treat niches with their next-gen combination regimens, especially treatment-experienced patients who failed on prior direct-acting antiviral therapy. Merck also is studying injectable drug users in an effort to eradicate HCV entirely.
UK HTA gives provisional backing to Merck’s once-daily fixed-dose hepatitis C combo Zepatier after the US drug maker offers an undisclosed price cut.
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.